Shernan Holtan, MD, University of Minnesota, Minneapolis, MN, discusses unmet needs in graft-versus-host disease (GvHD) and challenges to address when treating patients. Dr Holtan highlights the importance of exploring GvHD treatment options that are not overly immunosuppressive, highlighting the promise of regenerative medicine. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.